# GangaGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gangagen

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.gangagen.com
- Total disclosed funding: $5.4M
- Latest round: Series E (Nov 24, 2008)
- Investors on record: 3

## About

GangaGen Inc. is a biotechnology company that develops innovative treatments for drug-resistant bacterial infections, focusing on multidrug-resistant bacteria and providing therapeutic solutions for challenging healthcare needs.Founded in Palo Alto, US, GangaGen Inc. specializes in developing therapies targeting bacterial infections, particularly pneumonia caused by Klebsiella pneumoniae. The company has secured funding through a Series E round, raising USD 5.4 mn in November 2008 from investors including ATEL Capital Group, ICF Ventures, and Otsuka Pharmaceutical Co., Ltd. It operates without any known subsidiaries or parent companies, and there are no documented pivots in its business strategy. The company’s founder has not been specifically named in available resources.GangaGen is focused on developing novel treatments for drug-resistant bacterial infections, specifically targeting multidrug-resistant bacteria. Its core product, Klebicin, addresses pneumonia caused by Klebsiella pneumoniae, offering solutions for patients unresponsive to conventional treatments. The company’s products are utilized in healthcare settings, benefiting a diverse clientele that includes healthcare providers, pharmaceutical partners, and research institutions, primarily in North America and Europe, where antibiotic resistance is a significant challenge.GangaGen generates revenue through strategic partnerships and collaborations aimed at advancing its research programs, notably for Klebicin. Revenue is derived from agreements with healthcare providers and pharmaceutical companies, which may include licensing agreements or milestone payments linked to specific development phases. The pricing structure is designed to align with healthcare systems' needs, reflecting the value of its innovative therapies in tackling critical medical challenges.GangaGen plans to utilize the proceeds from the USD 5.4 mn Series E round to further develop Klebicin and explore new product launches. The company aims to strengthen its market presence in North America and Europe while considering potential expansions into other regions affected by antibiotic-resistant infections by the end of 2009. The recent funding will support research and development efforts to enhance its product pipeline and address growing healthcare demands.

## Funding rounds

- Series E, Nov 24, 2008, $5.4M — ICF Ventures, ATEL Capital Group, Otsuka Pharmaceutical Co., Ltd.

## Investors

- ICF Ventures (https://capitalatlas.ai/funds/icf-ventures) — Series E
- ATEL Capital Group (https://capitalatlas.ai/funds/atel-capital-group) — Series E
- Otsuka Pharmaceutical Co., Ltd. — Series E